Lactobacillus reuteri in children with functional abdominal pain (FAP)

Journal of Paediatrics and Child Health

Volumn 50, Issue 10, 2014, Pages E68-E71

  Romano, Claudio ^a   Ferrau', Valeria ^a   Cavataio, Francesca ^b   Iacono, Giuseppe ^b   Spina, Massimo ^c   Lionetti, Elena ^c   Comisi, Fabrizio ^d   Famiani, Annalisa ^a   Comito, Donatella ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Ospedale dei Bambini G Di Cristina   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d Pediatric Unit Vittoria Hospital   (Italy)

Author keywords

functional abdominal pain; functional gastrointestinal disorders (FGID); probiotics

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ABDOMINAL PAIN; ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FUNCTIONAL ABDOMINAL PAIN; HUMAN; LACTOBACILLUS REUTERI; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DIET SUPPLEMENTATION; FOLLOW UP; GASTROINTESTINAL DISEASES; PAIN MEASUREMENT; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ABDOMINAL PAIN; ADOLESCENT; CHI-SQUARE DISTRIBUTION; CHILD; DIETARY SUPPLEMENTS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; LACTOBACILLUS REUTERI; MALE; PAIN MEASUREMENT; PROBIOTICS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84908221325     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2010.01797.x     Document Type: Article

References (38)

1. Shurman JV, Friesen CA, Danda CE, et al,. Diagnosing functional abdominal pain with the Rome II criteria: parent, child, and clinician agreement. J. Pediatr. Gastroenterol. Nutr. 2004; 38: 187-91.
2. Apley J, Nash M,. Recurrent abdominal pain: a field survey of 1000 school children. Arch. Dis. Child. 1958; 33: 165-70.
3. Rasquin A, Di Lorenzo C, Forbes D, et al,. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006; 130: 1527-37.
4. Rasquin-Weber A, Hyman PE, Cucchiara S, et al,. Childhood functional gastrointestinal disorders. Gut 1999; 45: 60-8.
5. Baber KF, Anderson J, Puzanova M, et al,. Rome II versus Rome III classification of functional gastrointestinal disorders in pediatric chronic abdominal pain. J. Pediatr. Gastroenterol. Nutr. 2008; 47: 299-302.
6. Huertas-Ceballos A, Macarthur C, Logan S,. Pharmacological interventions for recurrent abdominal pain (RAP) in childhood. Cochrane Database Syst. Rev. 2009; Jan 21 (1).
7. Nobaek S, Johansson M-L, Molin G, et al,. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am. J. Gastroenterol. 2000; 95: 1231-8.
8. Liebgrets T, Adam B, Bredack C, et al,. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-20.
9. Biancone L, Monteleone I, Del Vecchio Blanco G, et al,. Residential bacterial flora and immune system. Dig. Liver Dis. 2002; 34 (Suppl. 2): S37-43.
10. Whorwell PJ, Altringer L, Morel J, et al,. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 2006; 101: 1581-90.
11. Rosander A, Connolly E, Roos S,. Removal of antibiotic resistance plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain L. reuteri DSM 17938. Appl. Environ. Microbiol. 2008; 74: 6032-40.
12. Wolf BW, Wheeler K, Ataya D, et al,. Safety and tolerance of Lactobacillus reuteri supplementation to a population infected with the human immunodeficiency virus. Food Chem. Toxicol. 1998; 36: 1085-94.
13. Valeur N, Engel P, Carbajal N, et al,. Colonization and immunomodulation by Lactobacillus reuteri ATCC 55730 in the human gastrointestinal tract. Appl. Environ. Microbiol. 2004; 70: 1176-81.
14. Böttcher MF, Abrahamsson TR, Fredriksson M, et al,. Low breast milk TGF-β2 is induced by Lactobacillus reuteri supplementation and associates with reduced risk of sensitization during infancy. Pediatr. Allergy Immunol. 2008; 19: 497-504.
15. Eom T-H, Oh E-Y, Kim Y-H, et al,. The therapeutic effect of Lactobacillus reuteri in acute diarrhea in infants and toddlers. Korean J. Ped. 2005; 48: 986-9.
16. Weizman Z, Asli G, Alsheikh A,. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005; 115: 5-9.
17. Savino F, Pelle E, Palumeri E, et al,. Lactobacillus reuteri ATCC 55730 versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 2007; 119: 124-30.
18. Indrio F, Riezzo G, Raimondi F, et al,. The effects of probiotics on feeding tolerance, bowel habits, and gastrointestinal motility in preterm newborns. J. Pediatr. 2008; 152: 801-6.
19. Chambers CT, Craig KD,. An intrusive impact of anchors in children's faces pain scales. Pain 1998; 78: 27-37.
20. Roth-Isigkeit A, Thyen U, Stoven H, et al,. Pain among children and adolescent: restrictions in daily living and triggering factors. Pediatrics 2005; 115: e152-62.
21. Gieteling MJ, Bierma-Zeinstra SMA, Passchier J, et al,. Prognosis of chronic or recurrent abdominal pain in children. J. Pediatr. Gastroenterol. Nutr. 2008; 47: 316-26.
22. Alak JI, Wolf BW, Mdurrvwa EG, et al,. Supplementation with Lactobacillus reuteri or L. acidophilus reduced intestinal shed ding of cryptosporidium parvum oocystis in immunodeficient C57BL/6 mice. Cell Mol. Biol. 1999; 45: 855-63.
23. Shornikova A, Casas IA, Mykkanen H, et al,. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis. Pediatr. Infect. Dis. J. 1997; 16: 1103-7.
24. Weizman Z, Alsheikh A,. Safety and tolerance of a probiotic formula in early infancy comparing two probiotic agents: a pilot study. J. Am. Coll. Nutr. 2006; 25: 415-9.
25. Chambers CT, Giesbrecht K, Craig KD, Bennett SM,. Huntsman E 1999; A comparison of faces scales for the measurement of pediatric pain: children's and parents' ratings. Pain 1999; 83: 25-35.
26. Hezco PB, Strus M, Kochan P,. Critical evaluation of probiotic activity of lactic acid bacteria and their effects. J. Physiol. Pharmacol. 2006; 57 (Suppl. 9): 5-12.
27. Sen S, Mullan M, Parker TJ, et al,. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig. Dis. Sci. 47: 261-50.
28. Guarner F, Malagelada J,. Gut flora in health and disease. Lancet 2003; 361: 512-9.
29. O'Mahony L, McCarthy J, Kelly P, et al,. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-55.
30. Gawronska A, Dziechciarz P, Horvath A, Szajewska H,. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment. Pharmacol. Ther. 2007; 25: 177-84.
31. Niv E, Naftali T, Hallak R, et al,. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome-a double blind, placebo-controlled, randomized study. Clin. Nutr. 2005; 24: 925-31.
32. Lionetti E, Miniello VL, Castellaneta SP, et al,. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomised placebo controlled trial. Aliment. Pharmacol. Ther. 2006; 24: 1461-8.
33. Spiller RC,. Infection, immune function, and functional gut disorders. Clin. Gastroenterol. Hepatol. 2004; 2: 445-55.
34. Van Ginkel R, Voskuijl WP, Benninga MA, et al,. Alterations in rectal sensitivity and motility in childhood irritable bowel syndrome. Gastroenterology 2001; 120: 31-8.
35. Lievin V, Peiffer I, Hudault S, et al,. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 2000; 47: 646-52.
36. Ma D, Forsythe P, Bienenstock J,. Live Lactobacillus reuteri is essential for the inhibitor effect on tumor necrosis factor alpha-induced interleukine-8 expression. Infect. Immun. 2004; 72: 5308-14.
37. Ma X, Mao YK, Wang B, Huizinga JD, Bienenstock J, Kunze WA,. Lactobacillus reuteri ingestion prevents hyperexcitability of colonic DRG neurons induced by noxious stimuli. Am. J. Physiol. Gastrointest. Liver Physiol. 2009; 296: G868-75.
38. Storr MA, Yuce B, Andrews CN, et al,. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol. Motil. 2008; 20: 857-68.